Robbie Ettinger
About Robbie Ettinger
Robbie Ettinger is an Associate in Investments at Roivant Sciences, where he has worked since 2023. He has a background in evaluating clinical stage therapeutics and experience in business development and product management.
Work at Roivant Sciences
Robbie Ettinger currently serves as an Associate in Investments at Roivant Sciences, a role he has held since 2023. Prior to this position, he worked as a Senior Analyst in Investments from 2021 to 2023 and as an Analyst in Investments from 2020 to 2021. His tenure at Roivant Sciences spans three years, during which he has gained experience in evaluating clinical stage therapeutics across various therapeutic areas. This experience informs his investment strategies and decision-making processes.
Education and Expertise
Robbie Ettinger studied at Cornell University, where he earned a Bachelor of Science in Applied Economics and Management from 2015 to 2018. He also attended The Hong Kong University of Science and Technology, focusing on Global Business & Management in 2018. His educational background in behavioral economics enhances his capabilities in biotech investing and provides a solid foundation for his analytical skills in the investment sector.
Background
Robbie Ettinger has a diverse professional background that includes experience in product management and talent acquisition. He worked as a Product Management Intern at eBay in two different capacities, focusing on Search Experience and Consumer Selling from 2017 to 2018. Additionally, he held various roles at Cornell Strategic Consulting, including Chief Operating Officer and Project Manager, which contributed to his understanding of business development and organizational growth.
Achievements
Throughout his career, Robbie Ettinger has developed expertise in evaluating clinical stage therapeutics and business development. His involvement in talent acquisition has provided him with insights into team building and organizational growth. His experience across multiple roles in investment and product management positions him as a knowledgeable professional in the biotech investment landscape.